© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > BMS-986144
<< Back to November
pan-genotype HCV NS3/4A protease inhibitor
proj. oral QD dosing, well-tolerated in rodent
deuteration reduced CYP TDI
J. Med. Chem., Nov. 23, 2020
Bristol-Myers Squibb, NJ + MA + CT + IN
Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor
Unlock this content with a Premium membership to read it now.